New drug for psoriasis approved by TGA

Posted 5 years ago

ILUMYA™ (tildrakizumab) has been approved by the Australian Therapeutic Goods Administration (TGA) for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy.

ILUMYA™ is an IgG1/κ monoclonal antibody that specifically binds to the p19 protein subunit of the interleukin 23 (IL-23) cytokine and inhibits its interaction with the IL-23 receptor, without binding to IL-12, leading to inhibition of the release of pro-inflammatory cytokines and chemokines.

The recommended dose of ILUMYA™ is 100mg at weeks 0, 4, 16 and then every 12 weeks thereafter.

Please review Product Information before prescribing or call Sun Pharma on 1800 726 229.